If you have been reading about Reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
glycoside Any chemical compound consisting of a carbohydrate molecule covalently bonded to another molecule containing a hydroxyl group (including other carbohydrates) via one or more C–O glycosidic bonds. When all of the compound's substituents are carbohydrates, the glycoside is a polysaccharide.
Morphine is a precursor in the manufacture of several opioids such as dihydromorphine, hydromorphone, hydrocodone, and oxycodone as well as codeine, which itself has a large family of semi-synthetic derivatives.
Research indicates that systematic physical stimuli from standard electronic devices, such as tablets with headphones, may treat injured nervous systems online by modulating neuronal plasticity. Evidence suggests that teleneurotherapy could enhance neurological treatment if it incorporates the therapeutic effect of a systematic abiotic impact of physical forces with key parameters of mother-fetus interaction. Recent research has shown therapeutic effects when implementing the APIN method in the online treatment of patients with various neurological conditions. Telenutrition refers to the use of video conferencing or telephony to provide online consultations by nutritionists or dieticians. Telerehabilitation (or e-rehabilitation) is the delivery of rehabilitation services over telecommunication networks and the Internet. Most services fall into two categories: clinical assessment (evaluating the patient's functional abilities in their environment) and clinical therapy.
=== Moffatt oxidation === In combination with dimethyl sulfoxide (DMSO), DCC affects the Pfitzner–Moffatt oxidation. This procedure is used for the oxidation of alcohols to aldehydes and ketones. Unlike metal-mediated oxidations, such as the Jones oxidation, the reaction conditions are sufficiently mild to avoid over-oxidation of aldehydes to carboxylic acids. Generally, three equivalents of DCC and 0.5 equivalents of proton source in DMSO are allowed to react overnight at room temperature. The reaction is quenched with acid.
Sources: en.wikipedia.org
=== EC 7.2 Catalysing the translocation of inorganic cations and their chelates === This subclass contains translocases that transfer inorganic cations (metal cations). Based on the reaction they're linked to, EC 7.2 can be further classified into:
The Italian government, presided over by Emilio Colombo after the resignation of Mariano Rumor, appealed to the people of Reggio Emilia to end the violence. Otherwise, it promised the use of force. For the first time in the history of the Italian Republic, the government sent in the army and carabinieri. Even far-left parties, including the Communists and the PSIUP, condemned the uprising, decrying it as parochial and non-proletarian, often clashing with their own voter base. On 23 February 1971, after 10 months of rioting, the revolt ceased given a compromise with the regional government. The Prime Minister, meeting with the president of the Calabria Region, Antonio Guarasci (CD), and regional politicians of various parties, assembled the Colombo Package, which sought to involve all parties: Catanzaro would be the regional capital, while Reggio would host the regional council; Cosenza would be the site of Calabria's first university (University of Calabria), while Gioia Tauro would become the fifth national steel hub and a chemical factory would be established in Saline Joniche. The agreement was accepted by the populace, but the steel plant was never built, while the chemical plant, although built, ceased production almost immediately due to Ministry of Health provisions that declared the feedstocks it produced to be carcinogenic. In the 1972 general elections the scales shifted in favor of the right, which won 27% of the vote and became the leading party in Reggio and Ciccio Franco was elected to the Senate.
Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection. Gastrointestinal side-effects tend to be strongest at the beginning of treatment period and subside over time. Other serious side effects may include angioedema, pancreatitis, gallbladder disease, and kidney problems. Use in pregnancy and breastfeeding is of unclear safety. A boxed warning in the US prescribing information cautions that medullary thyroid cancers have been observed in rats treated with liraglutide, but it is "unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, as relevance to humans of such tumors in rodents has not been determined."
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.